According to the Zhitong Finance App, China Biotech Services (08037.HK) announced that the Group is expected to obtain a net profit of not less than HK$15 million within the six months ending June 30, 2026. In contrast, the net loss for the six months ended June 30, 2025 was approximately HK$37 million. The anticipated shift from net loss to net profit is mainly due to possible non-cash and unrealized fair value gains of HK$77 million to HK$87 million on convertible bonds, which were offset by (i) an increase in financing costs of approximately HK$9 million due to the company's issuance of convertible bonds with a principal amount of US$35 million in February 2026; (ii) no non-recurring compensation income of approximately HK$14 million (which was recognized as other income in the same period in 2025).

According to the Zhitong Finance App, China Biotech Services (08037.HK) announced that the Group is expected to obtain a net profit of not less than HK$15 million within the six months ending June 30, 2026. In contrast, the net loss for the six months ended June 30, 2025 was approximately HK$37 million. The anticipated shift from net loss to net profit is mainly due to possible non-cash and unrealized fair value gains of HK$77 million to HK$87 million on convertible bonds, which were offset by (i) an increase in financing costs of approximately HK$9 million due to the company's issuance of convertible bonds with a principal amount of US$35 million in February 2026; (ii) no non-recurring compensation income of approximately HK$14 million (which was recognized as other income in the same period in 2025).